Opinion · 4 Feb 2026
Conference abstractPublished 23 Nov 2012
EU Regulatory Affair’s
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Background to regulatory affairs The European legislative framework Marketing Authorisation Applications Labels and leaflets European Procedures Lifecycle management, including variations
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Short communication · 29 Nov 2025
Strategic Pharmaceutical Regulatory Affairs for Global Success
Commentary · 30 Apr 2025
Drug-Toxicology and Its Role in Preventing Drug-Induced Harm: Focus on Clinical Toxicology and Regulatory Affairs
Commentary · 31 Mar 2025
Regulatory Affairs in Clinical Trials: Aligning Global Compliance with Ethical Research Standards
Perspective · 31 Mar 2025
The Regulatory Affairs Blueprint for Successful Drug Development
More from this journal
The newest in Pharmaceutical Regulatory Affairs: Open Access.
Article · 13 Feb 2026
Regulatory Scenario of Pharmaceuticals during COVID-19 Pandemic in India
Article · 11 Feb 2026
EU GMP Annex 1 of 2022: A View in Depth
Article · 11 Feb 2026
Standard Formats Used in Drug Regulatory Submissions and Software Used
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPharmaceutical Regulatory Affairs: Open Access
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Nagesh Maddula”

